You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Taltz ® (ixekizumab) injection
80 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can Taltz® (ixekuzumab) be given at doses greater than 80mg?
Neither efficacy nor safety has been adequately studied for dosage greater than that described in the prescribing information.
Approved Dosing
Plaque Psoriasis
Adults
Ixekizumab is administered by subcutaneous (SC) injection. The recommended dosage in adults with moderate-to-severe plaque psoriasis is
- 160 mg (two 80-mg injections) at week 0
- 80 mg at weeks 2, 4, 6, 8, 10, and 12, then
- 80 mg every 4 weeks (Q4W).1
Pediatric Patients
Ixekizumab is administered by SC injection. The recommended dosage in pediatric patients from 6 to less than 18 years of age with moderate-to-severe plaque psoriasis is
- greater than 50 kg: 160 mg (two 80-mg injections) at week 0, then 80 mg Q4W
- 25 to 50 kg: 80 mg at week 0, then 40 mg Q4W, and
- less than 25 kg: 40 mg at week 0, then 20 mg Q4W.1
Psoriatic Arthritis
Ixekizumab is administered by SC injection. The recommended dose is
- 160 mg (two 80-mg injections) at week 0, then
- 80 mg Q4W.1
For psoriatic arthritis patients with coexistent moderate-to-severe plaque psoriasis, use the dosing regimen for adult plaque psoriasis.1
Ixekizumab may be administered alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) (eg, methotrexate).1
Axial Spondyloarthritis
Ankylosing Spondylitis
Ixekizumab is administered by SC injection. The recommended dosage is 160 mg (two 80-mg injections) at week 0, followed by 80 mg Q4W.1
Non-radiographic Axial Spondyloarthritis
Ixekizumab is administered by SC injection. The recommended dose is 80 mg Q4W.1
Enclosed Prescribing Information
TALTZ® (ixekizumab) injection, for subcutaneous use, Lilly
Reference
1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.
Date of Last Review: September 10, 2026